Cargando…
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials
INTRODUCTION: Plaque psoriasis can significantly impact patients’ quality of life. We assessed psychometric properties of the Psoriasis Symptoms and Impacts Measure (P-SIM), developed to capture patients’ experiences of signs, symptoms and impacts of psoriasis. METHODS: Pooled, blinded, 16-week data...
Autores principales: | Warren, Richard B., Gottlieb, Alice B., Merola, Joseph F., Garcia, Llenalia, Cioffi, Christopher, Peterson, Luke, Pelligra, Christopher, Ciaravino, Valerie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484391/ https://www.ncbi.nlm.nih.gov/pubmed/34260044 http://dx.doi.org/10.1007/s13555-021-00570-4 |
Ejemplares similares
-
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial
por: Gottlieb, Alice B., et al.
Publicado: (2021) -
Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis
por: Gottlieb, Alice B., et al.
Publicado: (2020) -
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
por: Asahina, Akihiko, et al.
Publicado: (2023) -
Guselkumab for plaque psoriasis
Publicado: (2019) -
Bimekizumab for plaque psoriasis
Publicado: (2022)